AP
AGIO icon

Aspect Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Aspect Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-361
Closed -$9.83K – 711
2025
Q4 		$9.83K Hold
361
– – ﹤0.01% 273
2025
Q3 		$14.5K Hold
361
– – 0.01% 253
2025
Q2 		$12K Hold
361
– – 0.01% 263
2025
Q1 		$10.6K Hold
361
– – 0.01% 257
2024
Q4 		$11.9K Hold
361
– – 0.01% 260
2024
Q3 		$16K Hold
361
– – 0.01% 216
2024
Q2 		$15.6K Hold
361
– – 0.01% 212
2024
Q1 		$10.6K Hold
361
– – 0.01% 264
2023
Q4 		$8.04K Buy
+361
New +$8.09K 0.01% 278

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Aspect Partners's AGIO Position: Q1 2026 in Review

Aspect Partners sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 361 shares — an estimated $9.83K sold.

Aspect Partners first reported a position in AGIO in Q4 2023 and held it in 9 quarters. The position peaked at $16K in Q3 2024. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Aspect Partners reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aspect Partners sold 361 Agios Pharmaceuticals shares in Q1 2026, an estimated $9.83K.
  • Aspect Partners first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Aspect Partners's Agios Pharmaceuticals position peaked at $16K in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Aspect Partners's 13F filing for Q1 2026, filed 2 Apr 2026.